SEC Contract Filing

Filing Date: 2015-11-04

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>rlyp-ex101_543.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlyp-ex101_543.htm
</title>
</head>
<!-- NG Converter v4.0.2.6 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">LICENSE AGREEMENT</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:6.67%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">This License Agreement<font style="font-weight:normal;font-variant: normal;"> (the &#8220;</font><font style="font-variant: normal;">Agreement</font><font style="font-weight:normal;font-variant: normal;">&#8221;) is effective as of August 10, 2015 (the &#8220;</font><font style="font-variant: normal;">Effective Date</font><font style="font-weight:normal;font-variant: normal;">&#8221;) between </font>Relypsa, Inc<font style="font-variant: normal;">.</font><font style="font-weight:normal;font-variant: normal;">, a Delaware corporation located at 100 Cardinal Way, Redwood City, CA 94063, USA (&#8220;</font><font style="font-variant: normal;">Relypsa</font><font style="font-weight:normal;font-variant: normal;">&#8221;), and </font>Vifor Fresenius Medical Care Renal Pharma Ltd.<font style="font-weight:normal;font-variant: normal;">, a corporation that is established in accordance with Swiss laws and registered in the commercial registry under CH-320.3.033.350-1 and that is located at Rechenstrasse 37, CH-9014 St. Gallen, Switzerland (&#8220;</font><font style="font-variant: normal;">VFMCRP</font><font style="font-weight:normal;font-variant: normal;">&#8221;).&nbsp;&nbsp;Relypsa and VFMCRP are referred to individually as a &#8220;</font><font style="font-variant: normal;">Party</font><font style="font-weight:normal;font-variant: normal;">&#8221; and collectively as the &#8220;</font><font style="font-variant: normal;">Parties.</font><font style="font-weight:normal;font-variant: normal;">&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:6.67%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Relypsa is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat renal, cardiovascular and metabolic diseases, including the product known as Patiromer, a potassium binding agent which has been developed for the treatment of hyperkalemia;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:6.67%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, VFMCRP is a pharmaceutical company engaged in the development and commercialization of innovative and high quality products and therapies to improve the life of patients suffering from chronic kidney disease worldwide; and</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:6.67%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Relypsa is willing to grant to VFMCRP, and VFMCRP desires to obtain, a license under Relypsa&#8217;s intellectual property rights to develop and commercialize Patiromer in certain countries with product manufactured and supplied by or on behalf of Relypsa, on the terms and conditions set forth in this Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">AGREEMENT</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:6.67%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;">Now, Therefore<font style="font-weight:normal;font-variant: normal;">, in consideration of the foregoing and the covenants and promises contained in this Agreement and intending to be legally bound, the Parties agree as follows:</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:6.67%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;fo